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assisted laser desorption/ionization
(MALDI)-TOF MS, with its higher
resolution, is the capability of SELDI
to enrich low-abundance proteins
from complex matrices such as
plasma, through, for example, the
coupling of specific antibodies to the
chip surfaces (4 ). Such an approach
is an important methodologic aspect
in “second phase” proteomics, which
are characterized by repetitive inves-
tigation of the same protein to vali-
date the protein phenotype in large
population-based studies. This pro-
vides a basis for diagnostic progress
in personalized medicine (5 ). For
TTR, such an approach is relevant
not only in the diagnosis of TTR-
related amyloidosis but also in other
diseases.
The true problem with on-chip im-
munopurification is not the resolu-
tion of the MS, which can be solved
by use of specific available interfaces,
but the efficient coupling of the anti-
body to the chip surface. When an
on-chip immunoassay format is be-
ing used, it is important that the
protein chip retains the antibody in
an active state at high density. Re-
sults are greatly affected by function-
ality characteristics, such as the sta-
bility, affinity, and specificity of the
antibody. On the basis of studies
relating to microarrays, only 5%–20%
of commercially available antibodies
are suitable for one or the other mi-
croarray format (6 ).
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Validation of a Multiplex PCR Assay
for the Simultaneous Detection of
Human Papillomavirus and Chlamydia
trachomatis in Cervical PreservCyt
Samples
To the Editor:
Chlamydia trachomatis is the most
common sexually transmitted bacte-
rium worldwide (1 ) and a leading
cause of infertility in women (2 ).
Human papillomaviruses (HPVs) are
the most important single agent
causing carcinoma of the uterine cer-
vix (3 ). Combined molecular screen-
ing for C. trachomatis and HPV could
be justified given their propensity to
cause asymptomatic infections, par-
ticularly in high-risk groups. Fea-
tures of HPV infection of cells of the
uterine cervix are traditionally re-
ported by the Pap smear method (4 ).
The introduction of liquid-based cy-
tology, such as the ThinPrep® Pap
TestTM, has had the effect of improv-
ing the sensitivity of conventional
cytologic screening with the poten-
tial for HPV testing of residual cellu-
lar material in borderline or difficult
cases (5–7). The US Food and Drug
Administration (FDA) has recently
cleared a hybrid capture-based sys-
tem (HCII; Digene) for screening
women over 30 years of age as an
adjunct to Pap testing (8 ). Research-
ers have developed consensus prim-
ers for the detection of HPV DNA by
PCR (9, 10). We developed and eval-
uated a multiplex PCR for the simul-
taneous detection of HPV and C.
trachomatis from PreservCytTM (Thin-
Prep) solution.
The multiplex PCR was performed
on 100 cervical PreservCyt fluid
specimens collected from women at-
tending their general practitioners
for routine cervical screening. We
used the MY09/11 primers (9 ) for
HPV and plasmid primers for C. tra-
chomatis (11 ), which generated frag-
ments of 450 and 201 bp, respec-
tively. Primers for the human
-globin gene were included in the
multiplex as an internal DNA ampli-
fication control, generating a 110-bp
product (12 ) (see Fig. 1 in the Data
Supplement that accompanies the
online version of this Letter at http://
www.clinchem.org/content/vol51/
issue7/). The PCR mixture contained
5 pmol of each of the forward and
reverse primers of the MY09/11 and
CTP1/2 primer sets and 10 pmol of
each of the forward and reverse
primers of the PCO3/4 primer set,
200 M deoxynucleoside triphos-
phates, 10	 PCR buffer [containing
10 mM Tris-HCl (pH 8.3), 50 mM
KCl], 2 mM MgCl2, and 1 U of Plat-
inum Taq DNA polymerase (Invitro-
gen Ltd.) in a final volume of 20 L.
The PCR was initiated by a 10-min
denaturation and enzyme activation
step at 95 °C and was completed by a
10-min extension step at 72 °C. The
Table 1. Comparison of multiplex and single PCR for the detection of HPV and C.
trachomatis in PreservCyt cervical samples.
Sample cohort
Multiplex positive, n Single PCR positive, n
MY09/11a CTP1/2b MY09/11 GP5/6a CTP1/2 Hsp60b
GPc clinic (n  100) 21 2 24 14 2 2
GUM clinic (n  34) 10 34 10 10 34 34
a Primers for the detection of HPV.
b Primers for the detection of C. trachomatis.
c Women who attended general practitioner (GP) clinics for routine cervical screening.
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temperature cycles were as follows:
40 cycles of 30 s at 95 °C, 1 min at
57 °C, and 1 min at 72 °C.
The detection limit was estimated
on serial dilutions, from 108 to 101
copies/L, of cloned HPV MY09/11
and the C. trachomatis CTP PCR
product in the pCR® 2.1-TOPO® (In-
vitrogen Ltd). To evaluate the sensi-
tivity and specificity of the multiplex
PCR for the detection of each organ-
ism, we performed single PCRs on
all samples: one PCR that detects
HPV by use of the GP5/6 prim-
ers (10 ), generating a 150-bp prod-
uct; and one that detects C. trachoma-
tis by use of primers specific to the
hsp60 gene of C. trachomatis (sense,
5
-GAT GGT GTT ACC GTT GCG
A-3
; antisense, 5
-TAA TAA TCG
TCT TTA ACA ACG T-3
), generat-
ing a truncated version (309 bp) of a
previously described product (13 ).
PCRs were also performed with the
MY09/11 and CTP1/2 primer sets
singly.
In the screened population, 21%
(21 of 100) of samples were positive
for HPV by the multiplex PCR (Table
1). The MY09/11 primers identified 3
other samples as HPV positive that
were not detected by the multiplex
assay (Table 1). Either the MY09/11
or the GP5/6 primers confirmed
all 21 of the samples positive by the
multiplex assay. Two samples were
positive for C. trachomatis in the mul-
tiplex assay (Table 1). These were
confirmed positive by the CTP1/2
and Hsp60 primers in single PCRs,
and no additional positive samples
were detected. A positive sample
was defined as positive by either the
multiplex or any of the single PCRs
for that organism. The sensitivity
and specificity of the multiplex with
respect to single PCR for the detec-
tion of HPV in the opportunistically
screened samples were 89% (95%
confidence interval, 70%–97%) and
100% (94%–100%; Table 1). The mul-
tiplex assay was 100% specific and
sensitive for the detection of C. tra-
chomatis with respect to single PCR in
the screened population (Table 1).
To estimate the diagnostic sensitiv-
ity of the multiplex assay for the
detection of C. trachomatis, we per-
formed multiplex PCR on 34 Preserv-
Cyt fluid specimens from women
attending a genitourinary (GUM)
outpatient clinic who had tested pos-
itive for C. trachomatis by the LCx
(Abbott Laboratories). The sensitiv-
ity of the multiplex assay for the
detection of C. trachomatis in the
GUM clinic population was 100%
with respect to the commercial LCx
assay (Table 1). Ten of the 34 samples
were positive for HPV by the multi-
plex assay. These results were con-
firmed by single PCRs (Table 1). The
multiplex assay could detect as few
as 100 copies of the C. trachomatis
plasmid and 100 copies of the HPV
genome per microliter of extracted
DNA.
This is the first study looking at the
detection of both HPV and C. tracho-
matis from a single ThinPrep sample
by use of multiplex PCR. This simple
multiplex is rapid and could be used
to screen cervical ThinPrep samples
for both HPV and C. trachomatis, par-
ticularly in a high-risk population.
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Detection of Heavy Chain Disease by
Capillary Zone Electrophoresis
To the Editor:
Luraschi et al. (1 ) recently published
the first report describing the use of
capillary zone electrophoresis (CZE)
coupled with immunosubtraction to
detect and characterize low concen-
trations of free  heavy chains in
serum. By contrast, we describe a
case in which CZE failed to detect
and characterize  heavy chain dis-
ease.
A 90-year-old woman who com-
plained of weight loss presented
with progressive enlargement of the
left parotid gland, splenomegaly,
and palpable inguinal lymph node
1302 Letters
